'Life-changing' MS drug to help people walk now on NHS in England

Fampridine, the first drug to aid people with multiple sclerosis in regaining the ability to walk, is now on the NHS in England. By enhancing nerve signals, this medication facilitates easier movement and independent living for certain individuals. Aysen Slack, who had previously paid privately for the expensive medication, believes the shift to the NHS will make a significant difference.

Up to 5,000 people in England could potentially benefit from this drug annually. The drug is already accessible in other parts of the UK. Multiple sclerosis, an autoimmune condition, results from the immune system targeting the protective myelin sheath surrounding nerve cells, hindering the nerves' ability to transmit electrical signals to various body parts, including those essential for precise muscle control needed for walking.

Clinical trials revealed that approximately four out of ten individuals taking fampridine experienced improvements in walking speed and duration. This improvement could mean the difference between navigating the house independently or requiring assistance at home, or enabling people to venture out and reconnect with friends and family.

The current NHS support for MS patients comprises physiotherapy and walking aids. The drug had been previously rejected by the NHS in England due to perceived lack of value for money, although it became available in Wales, Scotland, and Northern Ireland. Aysen Slack, a 65-year-old resident of Eastbourne, opted to pay privately for the drug after hearing about its potential benefits.

She stated that fampridine was working well for her, but the high cost eventually necessitated discontinuation. Slack expressed that the news of fampridine being added to the NHS was great and that she would be eager to give it another try. My mobility has significantly declined, and even within my flat, I now rely on sticks for support, she added.

Improving my walking would make a tremendous difference in my life. Over 120,000 people in England live with MS, but only around 5,000 individuals annually will be eligible - determined by the severity of their walking difficulties. NHS national medical director, Prof Frankie Swords, emphasized that walking difficulties can profoundly impact the freedom and independence of individuals with MS. This signal-boosting medication has the potential to be life-changing for thousands of patients.

Even a modest improvement could facilitate easier navigation around the house, increased confidence when venturing out, and enhanced independence in daily living. Ceri Smith of the MS Society expressed delight at the news, as the drug could prove life-changing for many, enabling individuals to live more independently or maintain employment.

Studies associated with the MS trial suggest the possibility of repairing damage caused by the condition.